Skip to main content

and
Your search also matched 3 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis

Include preview-only content
  1. Article

    Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

    A correction to this paper has been published: https://doi.org/10.1007/s11523-021-00808-3

    Yeonghak Bang, Changhoon Yoo, Sara Lonardi, Hyung-Don Kim in Targeted Oncology (2021)